Keyphrases
Adrenoleukodystrophy
100%
Erucic Acid
63%
Sjögren's Syndrome
63%
Neurological Symptoms
59%
Clinical Efficacy
50%
Dehydrogenase Enzyme
36%
Phenotypic Expression
36%
Sjögren-Larsson
36%
Molecular Genetics
36%
Specific mutation
27%
Phenotypic Variation
27%
Fatty Aldehyde Dehydrogenase
27%
Fatty Acid Metabolism
27%
Fatty Alcohols
27%
L-2-hydroxyglutaric Aciduria
18%
Intravenous Immunoglobulin (IVIg)
18%
Immune Globulin Therapy
18%
Metabolism
16%
Clinical Research Center
10%
General Clinical
10%
Alcohol Metabolism
10%
Autoimmune Response
9%
Dietary Modification
9%
Patient Symptoms
9%
Metabolic Investigation
9%
Long-chain Polyunsaturated Fatty Acids (LC-PUFA)
9%
Leukocytes
9%
Fat Restriction
9%
Bilevel Therapy
9%
Aciduria
9%
Adrenomyeloneuropathy
9%
Long-chain Fatty Acids
9%
Immunological Response
9%
Dietary Supplementation
9%
Diet Therapy
9%
Symptomatic Patients
9%
Genetic Disease
6%
Genetic Heterogeneity
6%
Alcohol Consumption
6%
Biochemistry, Genetics and Molecular Biology
Adrenoleukodystrophy
81%
Erucic Acid
63%
Sjögren-Larsson Syndrome
45%
Oxidoreductase
36%
Molecular Genetics
36%
Fatty Alcohol
31%
Aldehyde Dehydrogenase
27%
Fatty Aldehyde
27%
Fatty Acid Metabolism
27%
Ethanol Metabolism
27%
Leukocyte
18%
Metabolic Pathway
13%
Very Long Chain Fatty Acid
9%
Dietary Fat
9%
Fibroblast
9%
Normal Human
9%
Medicine and Dentistry
Adrenoleukodystrophy
81%
Erucic Acid
63%
Neurologic Disease
50%
Fatty Alcohol
34%
Alcohol Metabolism
28%
Sjögren-Larsson Syndrome
27%
Fatty Acid Metabolism
27%
Aciduria
18%
Leukocyte
18%
Fat Intake
9%
Diet Supplementation
9%
Skin Fibroblast
9%
Phenotypic Variation
9%
Erythrocyte
9%
Long Chain Fatty Acid
9%
Symptom
7%